Indian healthcare market to hit $372 billion by 2022, says Assocham

By: |
New Delhi | December 03, 2017 6:12 PM

India's healthcare market may see threefold jump in value terms to USD 372 billion by 2022, driven by growing incidence of lifestyle diseases and rising demand for affordable healthcare delivery systems, says a report.

india healthcare market, RNCOS, CAGR, gst, pharmaceutical sector, geriatric population,  health insurance penetrationThe report prepared by Assocham and research firm RNCOS said the value of the sector in 2016 stood at $110 billon and will see a compounded annual growth rate (CAGR) of 22 per cent. (Reuters)

India’s healthcare market may see threefold jump in value terms to $372 billion by 2022, driven by growing incidence of lifestyle diseases and rising demand for affordable healthcare delivery systems, says a report. The report prepared by Assocham and research firm RNCOS said the value of the sector in 2016 stood at $110 billon and will see a compounded annual growth rate (CAGR) of 22 per cent. Besides, the medical devices market in India, which was valued at $4 billion as of 2016, is likely to cross $11 billion mark by 2022 on the back of growing geriatric population, uptick in medical tourism and gradual decline in cost of medical services, the survey noted. Growing lifestyle diseases, rising demand for affordable healthcare delivery systems due to increasing healthcare costs, emergence of telemedicine, rapid health insurance penetration, mergers and acquisitions helping to reach untapped markets and government initiatives are driving healthcare market in India, it said.

With regard to impact of GST on the pharmaceutical sector, the report said GST will streamline taxation structure as also lead to ease of doing business by minimising cascading effect of many taxes applied to a product, rationalise supply chain, enable flow of seamless tax credit, lower manufacturing cost and cost of technology and make healthcare affordable. “Increasing expenditure on research and development (R&D), rising collaborations between Indian and foreign companies, reduction in product approval time and other such factors are driving the growth of Indian pharmaceutical market,” the report noted.

 

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Jio-bp to sell premium fuels at no extra cost; EV charging, battery swap, 24×7 retail at RIL’s fuel stations
2Current, future sentiment index in real estate at all-time high: Report
3Kotak Mahindra Bank reports 7 pc fall in September quarter profit at Rs 2,032 crore